Elli Papaemmanuil

You absolutely need to hear about Elli Papaemmanuil, this guy’s a total beast in the biotech and startup world. Basically, he’s been crushing it across academia, big pharma, and now the startup scene. His story is one of pure passion for fixing cancer with tech, and he’s not stopping anytime soon.

So, Elli’s got a solid academic background, he kicked things off with a BSc in Human Molecular Genetics from Glasgow, then went all in with a PhD in Human Population Genetics from London. After that, he didn’t stop. He did postdoc work at Cambridge, and he was a Junior Team Leader there, plus a Senior Postdoc at the Wellcome Trust Sanger Institute. Basically, the dude’s been deep in the gene game for years, working on how our DNA impacts health.

But here’s where it gets real interesting, his work at Memorial Sloan Kettering as an Assistant Professor in Computational Oncology. That’s where he really started merging the tech and cancer worlds. He was all about using data and algorithms to understand cancer better. No cap, this guy saw that genomics could be a big change for precision medicine.

Then, he jumped into the corporate world with Deloitte as an IT Consultant. That’s where he learned how to scale tech solutions and really get how businesses work behind the scenes. It’s like he’s got the perfect mix of hardcore research chops and business hustle.

In 2020, Elli took all that experience and co-founded Isabl, a New York-based company all about whole-genome cancer diagnostics. Think about it: using the power of the full genome to detect and understand cancer better than ever. They got into Y Combinator’s W20 batch, that’s the big leagues for startups, proving he’s got what it takes to build something that matters.

What’s crazy is, Elli’s process shows he’s all about pushing the boundaries of what’s possible in medicine and tech. His motivation? Fixing cancer, saving lives, and making sure the latest genomics tech gets into the hands of docs and patients faster. Starting Isabl wasn’t just about building a biz, it was about turning years of research and experience into real-world impact.

Bottom line, Elli is that rare combo of scientist, entrepreneur, and innovator. He’s not just talking about changing cancer treatment; he’s actually doing it. And he’s just getting started.